Evidence map›Paper›PMID 39819288›Full record

ArticleBMC cancer2025

Characterization of the genomic landscape in liver oligometastatic NSCLC.

Rongxin Liao, Guangming Yi, Lu Shen, Xiao Xiao, Chuan Zeng, Liangzhong Liu, Hongjun Tang, Shunping Huang, Xiaoyue Zhang, Zaicheng Xu and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Rongxin Liao *Department of Cancer Center, Second Affiliated Hospital, Chongqing Medical University, Chongqing, China.
Guangming Yi *Department of Cancer Center, Second Affiliated Hospital, Chongqing Medical University, Chongqing, China.
Lu ShenGeneplus-Beijing, Beijing, China.
Xiao XiaoGeneplus-Beijing, Beijing, China.
Chuan ZengDepartment of Cancer Center, Second Affiliated Hospital, Chongqing Medical University, Chongqing, China.
Liangzhong LiuDepartment of Cancer Center, Second Affiliated Hospital, Chongqing Medical University, Chongqing, China.
Hongjun TangDepartment of Cancer Center, Second Affiliated Hospital, Chongqing Medical University, Chongqing, China.
Shunping HuangDepartment of Cancer Center, Second Affiliated Hospital, Chongqing Medical University, Chongqing, China.
Xiaoyue ZhangDepartment of Cancer Center, Second Affiliated Hospital, Chongqing Medical University, Chongqing, China.
Zaicheng XuDepartment of Cancer Center, Second Affiliated Hospital, Chongqing Medical University, Chongqing, China.
Zhenzhou YangDepartment of Cancer Center, Second Affiliated Hospital, Chongqing Medical University, Chongqing, China. yangzz@cqmu.edu.cn.
Yuan PengDepartment of Cancer Center, Second Affiliated Hospital, Chongqing Medical University, Chongqing, China. pengyuan1127@cqmu.edu.cn.

Funding

China Postdoctoral Science Foundation No.2022M710555Chongqing Municipal Health Commission Foundation No. 2023WSJK043Program for Youth Innovation in Future Medicine of Chongqing Medical University No. W0172Science and Technology Innovation Medical Development Foundation of Beijing No. KC2021-JX-0186-11
6 · The paper itself

Abstract

objectivesEmerging data have shown that local treatment could provide clinical benefit for non-small cell lung cancer (NSCLC) patients with oligometastasis. Liver metastases have the worst prognosis in advanced NSCLC, but the genomic characteristics of liver oligometastasis remain unclear. The aim of our study was to elucidate the molecular features of liver oligometastatic NSCLC.

methodsPaired liver metastatic tissue samples and peripheral blood from 32 liver oligometastatic NSCLC patients were concurrently collected for comprehensive genomic analysis using next-generation sequencing.

resultsA total of 206 mutated genes in 32 patients were detected, with a median of 4 mutations per sample. The most frequent alterations (> 10%) in liver oligometastasis were TP53 (72%), EGFR (50%), RB1 (19%) and SMARCA4 (12%). The co-occurrence rate of TP53 and RB1 in our cohort was significantly higher than that in the TCGA-LUAD cohort. Age, APOBEC, homologous recombination deficiency (HRD) and deficient mismatch repair (dMMR) established the mutational signature of liver oligometastatic NSCLC. The median tumor mutation burden (TMB) was 4.8 mutations/Mb. A total of 78.12% patients harbored at least one potentially actionable molecular alteration that may guide further targeted therapy according to the OncoKB evidence.

conclusionsOur study comprehensively delineated the genomic characteristics of liver oligometastatic NSCLC - such findings were helpful to better understand the distinct clinic-biological features of oligometastasis and optimize personalized treatment of this population.

Indexed as

Biomarkers, TumorCarcinoma, Non-Small-Cell LungLiver NeoplasmsLung NeoplasmsAdultAgedAged, 80 and overDNA HelicasesFemaleGenomicsHigh-Throughput Nucleotide SequencingHumansMaleMiddle AgedMutationNuclear ProteinsBiomarkers, TumorDNA HelicasesNuclear ProteinsRB1 protein, humanRetinoblastoma Binding ProteinsSMARCA4 protein, humanTP53 protein, humanTranscription FactorsTumor Suppressor Protein p53Ubiquitin-Protein LigasesGenomic profilingLiver oligometastasisNext-generation sequencingNSCLCTumor mutational burden

Identifiers

PMID39819288
PMCPMC11737069

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.